. | Twice-daily BIAsp 30 . | Thrice-daily BIAsp 30 . |
---|---|---|
n | 160 | 161 |
Completers (n) | 148 | 157 |
Age (years) | 54.4 ± 9.1 | 55.3 ± 8.8 |
Sex (male/female) | 88/72 | 79/82 |
BMI (kg/m2) | 24.3 ± 3.2 | 24.3 ± 3.1 |
Duration of diagnosed diabetes (years) | 7.7 ± 5.1 | 8.0 ± 4.8 |
Diabetes complications | ||
Retinopathy | 11.3 | 9.9 |
Nephropathy | 5.0 | 1.9 |
Neuropathy | 10.0 | 3.1 |
Macroangiopathy | 3.8 | 9.3 |
Baseline A1C | 9.52 ± 1.4 | 9.55 ± 1.5 |
Prior treatments with OADs | ||
One OAD | 11.9 | 18.0 |
Two OADs | 35.0 | 36.6 |
Three or more OADs | 53.1 | 45.3 |
Discontinuation from study* | ||
For adverse event | 3 (2) | 2 (1) |
For noncompliance | 8 (5) | 1 (1) |
For ineffective therapy | 1 (1) | 0 |
For other reasons | 0 | 1 (1) |
. | Twice-daily BIAsp 30 . | Thrice-daily BIAsp 30 . |
---|---|---|
n | 160 | 161 |
Completers (n) | 148 | 157 |
Age (years) | 54.4 ± 9.1 | 55.3 ± 8.8 |
Sex (male/female) | 88/72 | 79/82 |
BMI (kg/m2) | 24.3 ± 3.2 | 24.3 ± 3.1 |
Duration of diagnosed diabetes (years) | 7.7 ± 5.1 | 8.0 ± 4.8 |
Diabetes complications | ||
Retinopathy | 11.3 | 9.9 |
Nephropathy | 5.0 | 1.9 |
Neuropathy | 10.0 | 3.1 |
Macroangiopathy | 3.8 | 9.3 |
Baseline A1C | 9.52 ± 1.4 | 9.55 ± 1.5 |
Prior treatments with OADs | ||
One OAD | 11.9 | 18.0 |
Two OADs | 35.0 | 36.6 |
Three or more OADs | 53.1 | 45.3 |
Discontinuation from study* | ||
For adverse event | 3 (2) | 2 (1) |
For noncompliance | 8 (5) | 1 (1) |
For ineffective therapy | 1 (1) | 0 |
For other reasons | 0 | 1 (1) |
Data are means ± SD, percent, or n (%), unless otherwise indicated.
Adverse event withdrawals in the twice-daily treatment were anaphylaxis appendicitis and pain of waist; adverse event withdrawals in the thrice-daily treatment were nausea and acute myocardial infarction. The one “other” referred to refusal to inject insulin.